Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 54Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Neoplasm Metastasis 4Sarcoma, Ewing 3Neoplasms 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Ependymoma 2Colonic Neoplasms 2Xanthogranuloma, Juvenile 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Teratoma 1Recurrent Squamous Cell Lung Carcinoma 1

Interventions

palbociclib 1Letrozole 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Estrogen Receptor-positive Breast Cancer × palbociclib × Clear all
NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡